These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


109 related items for PubMed ID: 16147904

  • 1. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients.
    Zeng ZL, Sun J, Guo L, Li S, Wu MW, Qiu F, Jiang WQ, Lévi F, Xian LJ.
    Chronobiol Int; 2005; 22(4):741-54. PubMed ID: 16147904
    [Abstract] [Full Text] [Related]

  • 2. Circadian variation of plasma cortisol and whole blood reduced glutathione levels in nasopharyngeal carcinoma patients.
    Wu MW, Zeng ZL, Li S, Guo L, Zhang JX, Qiu F, Xian LJ.
    Ai Zheng; 2008 Mar; 27(3):237-42. PubMed ID: 18334110
    [Abstract] [Full Text] [Related]

  • 3. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
    Raida M, Kliche KO, Schwabe W, Häusler P, Clement JH, Behnke D, Höffken K.
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
    [Abstract] [Full Text] [Related]

  • 4. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ, Dong QM, Shi YX, Cao Y, Zhou ZM, Yuan ZY, Li S, Li H, Jiang WQ.
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB.
    Clin Cancer Res; 2006 Jan 15; 12(2):549-55. PubMed ID: 16428499
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006 Jan 15; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The stability of dihydropyrimidine dehydrogenase activity in colorectal cancer tissue after resection.
    Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Kamijo A, Saguchi T, Yasuda S, Tajima T, Makuuchi H, Murayama C.
    Oncol Rep; 2003 Jan 15; 10(4):867-9. PubMed ID: 12792736
    [Abstract] [Full Text] [Related]

  • 12. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y, Takahashi K, Saito T.
    Hepatogastroenterology; 2005 Jan 15; 52(66):1715-21. PubMed ID: 16334763
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.
    Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB.
    Cancer Res; 1993 Jun 15; 53(12):2816-22. PubMed ID: 8504424
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007 Jun 15; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 16. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
    Jiang H, Lu J, Ji J.
    Br J Pharmacol; 2004 Feb 15; 141(4):616-23. PubMed ID: 14744810
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
    Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, Kanamaru M, Hiratsuka A, Watabe T, Uematsu T.
    Clin Cancer Res; 2005 Jul 15; 11(14):5104-11. PubMed ID: 16033824
    [Abstract] [Full Text] [Related]

  • 19. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH, Lee AM, Mattison LK, Diasio RB.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [Abstract] [Full Text] [Related]

  • 20. [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
    Xiao JX, Han M, Li L, Zhu J, Chen LH, Bai PS.
    Zhonghua Yi Xue Za Zhi; 2005 Aug 10; 85(30):2136-9. PubMed ID: 16313827
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.